Tanya G K Bentley
Biographic Data
| ID | 6084269 |
|---|---|
| NAME | Tanya G K Bentley |
| GIVEN NAMES | Tanya G K |
| FAMILY NAME | Bentley |
| SIGNATURE | BENTLEY T G K |
| AFFILIATIONS | Partnership for Health Analytic Research |
| ORCID | 0000-0002-8835-9223 |
| VERIFIED | Yes |
| TOTAL WORKS | 5 |
| TOTAL CITATIONS | 21 |
| WORKS AS AUTHOR | 5 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2006 |
| LATEST PUBLICATION YEAR | 2019 |
| H-INDEX | 1 |
Increased Clinical and Economic Burden Associated With Peripheral Intravenous Catheter–Related Complications
The burden of complications associated with peripheral intravenous use is underevaluated, in part, due to the broad use, inconsistent coding, and lack of mandatory reporting of these devices. This study aimed to analyze the clinical and economic impact of peripheral intravenous-related complications on hospitalized patients. This analysis of Premier Perspective ® Database US hospital discharge records included admissions occurring between July 1,…
Tolerability of central nervous system symptoms among HIV-1 infected efavirenz users
Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor indicated for treatment of HIV-1 infection. Despite concern over EFV tolerability in clinical trials and practice, particularly related to central nervous system (CNS) adverse events, some observational studies have shown high rates of EFV continuation at one year and low rates of CNS-related EFV substitution. The objective of this study was to further examine the real-world rate…
Race and gender associations between obesity and nine health-related quality-of-life measures
A cost-effectiveness analysis of folic acid fortification policy in the United States
Objective To quantify the health and economic outcomes associated with changes in folic acid consumption following the fortification of enriched grain products in the USA. Design Cost-effectiveness analysis. Setting Annual burden of disease, quality-adjusted life years (QALY) and costs were projected for four steady-state strategies: no fortification, or fortifying with 140, 350 or 700 μg folic acid per 100 g enriched grain. The analysis consider…
Population-Level Changes in Folate Intake by Age, Gender, and Race/Ethnicity after Folic Acid Fortification
Objectives. We sought to quantify the impact of the 1998 US Food and Drug Administration (FDA) folic acid fortification policy by estimating folate intake at the population level. Methods. We analyzed total folate intake levels (from food and supplements) according to gender, age, and race/ethnicity, using data from 2 National Health and Nutrition Examination Surveys. We measured pre- and postfortification folate intake distributions, adjusted fo…
Population-Level Changes in Folate Intake by Age, Gender, and Race/Ethnicity after Folic Acid Fortification
Objectives. We sought to quantify the impact of the 1998 US Food and Drug Administration (FDA) folic acid fortification policy by estimating folate intake at the population level. Methods. We analyzed total folate intake levels (from food and supplements) according to gender, age, and race/ethnicity, using data from 2 National Health and Nutrition Examination Surveys. We measured pre- and postfortification folate intake distributions, adjusted fo…
Population-Level Changes in Folate Intake by Age, Gender, and Race/Ethnicity after Folic Acid Fortification
Objectives. We sought to quantify the impact of the 1998 US Food and Drug Administration (FDA) folic acid fortification policy by estimating folate intake at the population level. Methods. We analyzed total folate intake levels (from food and supplements) according to gender, age, and race/ethnicity, using data from 2 National Health and Nutrition Examination Surveys. We measured pre- and postfortification folate intake distributions, adjusted fo…
A cost-effectiveness analysis of folic acid fortification policy in the United States
Objective To quantify the health and economic outcomes associated with changes in folic acid consumption following the fortification of enriched grain products in the USA. Design Cost-effectiveness analysis. Setting Annual burden of disease, quality-adjusted life years (QALY) and costs were projected for four steady-state strategies: no fortification, or fortifying with 140, 350 or 700 μg folic acid per 100 g enriched grain. The analysis consider…
Race and gender associations between obesity and nine health-related quality-of-life measures
Tolerability of central nervous system symptoms among HIV-1 infected efavirenz users
Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor indicated for treatment of HIV-1 infection. Despite concern over EFV tolerability in clinical trials and practice, particularly related to central nervous system (CNS) adverse events, some observational studies have shown high rates of EFV continuation at one year and low rates of CNS-related EFV substitution. The objective of this study was to further examine the real-world rate…
Increased Clinical and Economic Burden Associated With Peripheral Intravenous Catheter–Related Complications
The burden of complications associated with peripheral intravenous use is underevaluated, in part, due to the broad use, inconsistent coding, and lack of mandatory reporting of these devices. This study aimed to analyze the clinical and economic impact of peripheral intravenous-related complications on hospitalized patients. This analysis of Premier Perspective ® Database US hospital discharge records included admissions occurring between July 1,…
Internal Medicine (5 works) · Medicine (5 works) · Demography (3 works) · Nutrition and Health in Aging (3 works) · Biology (2 works) · Demography (2 works) · Environmental health (2 works) · Folate and B Vitamins Research (2 works) · folic acid (2 works) · Food fortification (2 works)